Thomson Reuters To Provide Online Cancer Treatment Decision Support Tools For Tigerlily Foundation

Cancer Profiler Provides Patients with Treatment Information on www.tigerlilyfoundation.org

Ann Arbor, MI - Thomson Reuters has teamed with Tigerlily Foundation, an education and advocacy organization devoted to improving the quality of life for young women affected by breast cancer. Thomson Reuters is providing Tigerlily Foundation with its NexCura cancer Profiler Tools, which allow patients and caregivers to enter information on a cancer diagnosis and receive detailed treatment information based on the latest peer-reviewed research.

Now available on the Tigerlily Foundation home page, www.tigerlilyfoundation.org, the cancer Profiler Tools provide a step-by-step approach to help users better understand diagnostic tests, treatment options and, in some cases, possible outcomes based on the experience of similar people treated within clinical trials. All of the information is based on a database of peer-reviewed clinical research.

No other Internet offering produces such in-depth treatment information tailored to an individual’s specific diagnosis and clinical status. This individualized information helps patients have more informed discussions with their doctors, take charge of their health, and participate more fully in treatment decisions - with the aim of improving their medical prognoses.

“Tigerlily Foundation has galvanized amazing support for diagnosing early onset breast cancer and its Web site has become a beacon for young women searching for information on the disease,” said Alicia Moffat, vice president of Web operations for the Healthcare business of Thomson Reuters. “We are thrilled to be a part of the organization’s efforts to support and inspire young women affected by breast cancer.”

The Thomson Reuters cancer Profiler Tools use patented technology to lead users through an easy-to-follow questionnaire that matches the patient’s diagnosis, diagnostic results, and disease stage with the relevant treatment options.

“The cancer Profiler Tools are the ultimate resource to empower women and their families with the kind of detailed information they need to take control of their care,” said Maimah Karmo, Tigerlily Foundation president and founder. “One of the most important variables determining the outcome of the breast cancer diagnosis is informed, active dialogue between patient, family and doctors. These tools help move that conversation forward.”

Thomson Reuters’ Profiler Tools provide customized information about treatment options for more than 30 chronic diseases including cancer, cardiovascular, pulmonary and urologic conditions. They have been used by more than 1 million people on Web sites of the American Heart Association, American Lung Association, Lance Armstrong Foundation, and academic and commercial healthcare organizations. To learn more, visit www.nexcura.com.

About Thomson Reuters
The Healthcare business of Thomson Reuters produces insights, information, benchmarks and analysis that enable organizations to manage costs, improve performance and enhance the quality of healthcare. Thomson Reuters is the world’s leading source of intelligent information for businesses and professionals. We combine industry expertise with innovative technology to deliver critical information to leading decision makers in the financial, legal, tax and accounting, scientific, healthcare and media markets, powered by the world’s most trusted news organization. With headquarters in New York and major operations in London and Eagan, Minnesota, Thomson Reuters employs more than 50,000 people in 93 countries. Thomson Reuters shares are listed on the New York Stock Exchange (NYSE: TRI); Toronto Stock Exchange (TSX: TRI); London Stock Exchange (LSE: TRIL); and Nasdaq (NASDAQ: TRIN). For more information, go to www.thomsonreuters.com.